Evidence map›Paper›PMID 27575819›Full record

ArticlePloS one2016

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.

Michele Pohlen, Nils H Thoennissen, Jan Braess, Johannes Thudium, Christoph Schmid, Matthias Kochanek, Karl-Anton Kreuzer, Pia Lebiedz, Dennis Görlich, Hans U Gerth and 13 more

Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Michele PohlenDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Nils H ThoennissenDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Jan BraessDepartment of Medicine III, Hematology and Oncology, University Hospital Grosshadern, Munich, Germany.
Johannes ThudiumDepartment of Medicine III, Hematology and Oncology, University Hospital Grosshadern, Munich, Germany.
Christoph SchmidDepartment of Medicine II, Klinikum Augsburg, Augsburg, Germany.
Matthias KochanekDepartment of Medicine I, University Hospital Cologne, Cologne, Germany.
Karl-Anton KreuzerDepartment of Medicine I, University Hospital Cologne, Cologne, Germany.
Pia LebiedzDepartment of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany.
Dennis GörlichInstitute of Biostatistics and Clinical Research, University Muenster, Muenster, Germany.
Hans U GerthDepartment of Medicine D, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Christian RohdeDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Torsten KesslerDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Carsten Müller-TidowDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Matthias StelljesDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Carsten Hullermann
Thomas BüchnerDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Günter SchlimokDepartment of Medicine II, Klinikum Augsburg, Augsburg, Germany.
Michael HallekDepartment of Medicine I, University Hospital Cologne, Cologne, Germany.
Johannes WaltenbergerDepartment of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany.
Wolfgang HiddemannDepartment of Medicine III, Hematology and Oncology, University Hospital Grosshadern, Munich, Germany.
Wolfgang E BerdelDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Bernhard HeilmeierDepartment of Medicine II, Klinikum Augsburg, Augsburg, Germany.
Utz KrugDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
University Hospital Münster · DEUniversity Hospital Augsburg · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis retrospective, multicenter study aimed to reveal risk predictors for mortality in the intensive care unit (ICU) as well as survival after ICU discharge in patients with acute myeloid leukemia (AML) requiring treatment in the ICU. METHODS AND

resultsMultivariate analysis of data for 187 adults with AML treated in the ICU in one institution revealed the following as independent prognostic factors for death in the ICU: arterial oxygen partial pressure below 72 mmHg, active AML and systemic inflammatory response syndrome upon ICU admission, and need for hemodialysis and mechanical ventilation in the ICU. Based on these variables, we developed an ICU mortality score and validated the score in an independent cohort of 264 patients treated in the ICU in three additional tertiary hospitals. Compared with the Simplified Acute Physiology Score (SAPS) II, the Logistic Organ Dysfunction (LOD) score, and the Sequential Organ Failure Assessment (SOFA) score, our score yielded a better prediction of ICU mortality in the receiver operator characteristics (ROC) analysis (AUC = 0.913 vs. AUC = 0.710 [SAPS II], AUC = 0.708 [LOD], and 0.770 [SOFA] in the training cohort; AUC = 0.841 for the developed score vs. AUC = 0.730 [SAPSII], AUC = 0.773 [LOD], and 0.783 [SOFA] in the validation cohort). Factors predicting decreased survival after ICU discharge were as follows: relapse or refractory disease, previous allogeneic stem cell transplantation, time between hospital admission and ICU admission, time spent in ICU, impaired diuresis, Glasgow Coma Scale <8 and hematocrit of ≥25% at ICU admission. Based on these factors, an ICU survival score was created and used for risk stratification into three risk groups. This stratification discriminated distinct survival rates after ICU discharge.

conclusionsOur data emphasize that although individual risks differ widely depending on the patient and disease status, a substantial portion of critically ill patients with AML benefit from intensive care.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleHospital MortalityHumansIntensive Care UnitsLeukemia, Myeloid, AcuteMaleMiddle AgedMortalityMultivariate AnalysisOrgan Dysfunction ScoresRetrospective StudiesRisk Factors

Identifiers

PMID27575819
PMCPMC5004890
OpenAlexW2514575354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.